Live Program Date: Wednesday, April 23, 2025
Program Expiration: April 22, 2028
Program Number: 25EL-527

Educational Track: Technical/Clinical
Topics: Blood Donation & Collection, Patient Transfusion
Intended Audience: Hospitals, Immunohematology Reference Labs (IRL’s), Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Physicians, Research Scientists, Residents/Fellows, Scientists, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers

Faculty
(titles and affiliations at the time of the live program)
Directors/Moderator: Elizabeth St. Lezin, MD, Clinical Professor of Laboratory Medicine Emeritus, UCSF, San Francisco, CA
Speaker: John Manis, MD, Associate Professor Pathology, Harvard Medical School & Boston Children’s Hospital, Boston, MA

Program Description
For many patients with sickle cell disease (SCD), hematopoietic stem cell transplantation is unavailable due to lack of a matched donor. Gene therapy using autologous gene-edited stem cells has emerged as an option for these patients. Two gene therapy regimens have been approved by the FDA and additional clinical trials are underway. This program will provide background on gene therapy for SCD and an update on the status of SCD gene-editing clinical trials. The program will also address challenges in preparing products for patients enrolled in these trials and for the transfusion services providing transfusion support.

Learning Objectives
After participating in this educational activity, participants should be able to:

Demonstrate understanding of the role of gene therapy and gene-editing in the treatment of SCD.
Identify current FDA-approved gene therapy regimens and key gene-editing clinical trials in SCD.
Apply understanding of preparative transfusions for mobilization and collection of stem cells for SCD cell therapies.

How to Claim Continuing Education Credit

Single Viewers: if you registered as a single viewer, complete the evaluation found on the "CE Information" tab after watching the video. By submitting the evaluation, you are attesting to watching the presentation in its entirety.

Group Viewers: This is applicable for groups/facilities that purchased Group Viewing access for this program (registration will be verified prior to processing a group viewing attendance log). Group Viewing Coordinators should submit the attendance log to eLearning@aabb.org within 72 hours of the completion/viewing date. Once AABB receives an attendance log, each participant on the attendance log will be granted access as a single viewer to this program and will be required to complete the evaluation in order to claim continuing education credit. Each participant will be required to have an AABB account in order to access this program/platform. If a participant does not have an account, he/she can create one using the same email address provided on the attendance log.

John Manis MD

Harvard Medical School & Boston Children’s Hospital

Appearances